Patents Assigned to NSABP Foundation, Inc.
-
Patent number: 10166210Abstract: A gene expression signature identifies stage II colon cancer patients who will receive benefit from oxaliplatin. Oxaliplatin has been shown to lengthen the survival of colon cancer patients, when it is combined with 5-fluorouracil plus leucovorin (FULV) in NSABP clinical trial C-07. Gene expression signatures are used first to classify tumors with regard to their respective subtypes, enterocyte, TA, goblet, inflammatory and stem-like and detection of expression of the enterocyte subtype directs treatment of the patient with oxaliplatin.Type: GrantFiled: June 12, 2015Date of Patent: January 1, 2019Assignee: NSABP Foundation, Inc.Inventors: Katherine Lea Pogue-Geile, Nan Song, Soonmyung Paik
-
Publication number: 20180051348Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.Type: ApplicationFiled: August 11, 2017Publication date: February 22, 2018Applicants: Genomic Health, Inc., NSABP Foundation, Inc.Inventors: Joffre B. BAKER, John L. BRYANT, Soonmyung PAIK, Steven SHAK
-
Publication number: 20140348821Abstract: Methods of testing to identify and to treat a subset of colon cancer patients exhibiting dMMR tumor tissue, who derive significant clinical benefit from the addition of bevacizumab to standard adjuvant chemotherapy. The presence of a V600E BRAF mutation is also of significance.Type: ApplicationFiled: May 23, 2014Publication date: November 27, 2014Applicant: NSABP Foundation, Inc.Inventors: Katherine Lea Pogue-Geile, Soonmyung Paik
-
Patent number: 8868352Abstract: The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.Type: GrantFiled: March 16, 2011Date of Patent: October 21, 2014Assignees: Genomic Health, Inc., NSABP Foundation, Inc.Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
-
Publication number: 20140206545Abstract: The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.Type: ApplicationFiled: December 18, 2013Publication date: July 24, 2014Applicants: NSABP FOUNDATION, INC., GENOMIC HEALTH, INC.Inventors: Joffre B. BAKER, Wayne COWENS, Kim M. CLARK-LANGONE, James HACKETT, Drew WATSON, Soonmyung PAIK
-
Patent number: 8632980Abstract: The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.Type: GrantFiled: October 21, 2011Date of Patent: January 21, 2014Assignees: Genomic Health, Inc., NSABP Foundation, IncInventors: Joffre B. Baker, Wayne Cowens, Kim Langone, James Hackett, Drew Watson, Soonmyung Paik
-
Publication number: 20130251710Abstract: The present disclosure provides improved methods for identifying breast cancer patients that receive an increased benefit from the addition of a HER2-targeted therapy, for example adjuvant trastuzumab, to chemotherapy.Type: ApplicationFiled: May 8, 2013Publication date: September 26, 2013Applicant: NSABP Foundation, Inc.Inventors: Soonmyung Paik, Katherine Pogue-Geile, Patrick Gavin
-
Publication number: 20130102492Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.Type: ApplicationFiled: December 28, 2012Publication date: April 25, 2013Applicants: NSABP FOUNDATION, INC., GENOMIC HEALTH, INC.Inventors: GENOMIC HEALTH, INC., NSABP FOUNDATION, INC.
-
Patent number: 8367345Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.Type: GrantFiled: March 6, 2012Date of Patent: February 5, 2013Assignees: Genomic Health Inc., NSABP Foundation, Inc.Inventors: Wayne Cowens, Joffre B. Baker, Kim Clark-Langane, James Hackett, Drew Watson, Soonmyung Paik
-
Patent number: 8273537Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.Type: GrantFiled: October 25, 2010Date of Patent: September 25, 2012Assignees: Genomic Health, Inc., NSABP Foundation, Inc.Inventors: Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
-
Patent number: 8198024Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.Type: GrantFiled: January 19, 2011Date of Patent: June 12, 2012Assignees: Genomic Health, Inc., NSABP Foundation, Inc.Inventors: Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
-
Patent number: 8153378Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.Type: GrantFiled: January 29, 2010Date of Patent: April 10, 2012Assignees: Genomic Health, Inc., NSABP Foundations, Inc.Inventors: Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett, Drew Watson, Soonmyung Paik
-
Patent number: 8153379Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.Type: GrantFiled: October 25, 2010Date of Patent: April 10, 2012Assignees: Genomic Health, Inc., NSABP Foundation, Inc.Inventors: Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
-
Patent number: 8153380Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.Type: GrantFiled: October 25, 2010Date of Patent: April 10, 2012Assignees: Genomic Health, Inc., NSABP Foundation, Inc.Inventors: Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
-
Patent number: 8067178Abstract: The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.Type: GrantFiled: March 13, 2009Date of Patent: November 29, 2011Assignees: Genomic Health, Inc., NSABP Foundation, Inc.Inventors: Joffre B. Baker, Wayne Cowens, Kim Langone, James Hackett, Drew Watson, Soonmyung Paik
-
Publication number: 20110262434Abstract: The present disclosure provides improved methods for identifying breast cancer patients that receive an increased benefit from the addition of a HER2-targeted therapy, for example adjuvant trastuzumab, to chemotherapy.Type: ApplicationFiled: April 25, 2011Publication date: October 27, 2011Applicant: NSABP Foundation, Inc.Inventors: Soonmyung Paik, Katherine Pogue-Geile, Patrick Gavin
-
Patent number: 8029995Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.Type: GrantFiled: October 25, 2010Date of Patent: October 4, 2011Assignees: Genomic Health, Inc., NSABP Foundation, Inc.Inventors: Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
-
Patent number: 8026060Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.Type: GrantFiled: October 25, 2010Date of Patent: September 27, 2011Assignees: Genomic Health, Inc., NSABP Foundation, Inc.Inventors: Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
-
Patent number: 7939261Abstract: The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.Type: GrantFiled: March 18, 2009Date of Patent: May 10, 2011Assignees: Genomic Health, Inc., NSABP Foundation, Inc.Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
-
Patent number: 7930104Abstract: The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.Type: GrantFiled: November 4, 2005Date of Patent: April 19, 2011Assignees: Genomic Health, Inc., NSABP Foundation, Inc.Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak